Stockpolly
Search
Delisting risk
OTLK · NASDAQ · Biotechnology

Outlook Therapeutics (OTLK)

Develops and commercializes ophthalmic bevacizumab for wet age-related macular degeneration.

$0.6273
Pre-market−0.00 (−0.48%)
At close$0.6303(+1.16%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Sep 2023Q1 FY24Dec 2023Q2 FY24Mar 2024Q3 FY24Jun 2024Q4 FY24Sep 2024Q1 FY25Dec 2024Q2 FY25Mar 2025Q3 FY25Jun 2025Q4 FY25Sep 2025Q1 FY26Dec 2025Q2 FY26Mar 2026Q3 FY26Jun 2026
Revenue000000020−100
Cost of revenue000000001000
Gross profit00000001−1−100
121019202322121716121411
Research & development5514111310476453
86581012810109108
Selling & marketing000000000000
General & administrative8658012810109108
Other expenses000000000000
Operating income−12−10−19−20−23−22−12−16−17−13−14−11
−1−1−95642939−34−42−1010−9
Interest income000000000000
Interest expense003000000000
Other non-operating income40000004−3009
Income before tax−13−11−11444617−46−20−15−23−4−20
Income tax expense00000000−2000
Net income from continuing operations−13−11−11444617−46−20−13−23−4−20
Net income−13−11−11444617−46−20−13−23−4−20
EPS, basic−$1.00−$0.86−$8.01$1.91$0.31$0.72−$1.50−$0.55−$0.52−$0.38−$0.17−$0.80
EPS, diluted−$1.00−$0.86−$8.01−$0.89$0.31$0.72−$1.50−$0.55−$0.52−$0.38−$0.17−$0.80
Weighted average shares, basic131314231924313725252525
Weighted average shares, diluted131314251924313725252525
EBITDA−17−10−19−20−23−22−12−20−15−13−14−20
Depreciation & amortization000000000000
EBIT−17−10−19−20−23−22−12−20−15−13−14−20